The United States’ Food and Drug Administration (FDA) issued an emergency-use authorizing the use of a pair of anti-malaria drugs in a passionate and rapid bid to stop the spread of the virus.
The Health and Human Services Department (HHS) said in a statement;
The authorization would allow 30 million doses of hydroxychloroquine sulfate and 1 million doses of chloroquine phosphate to be donated to the Strategic National Stockpile. The doses of hydroxychloroquine sulfate were donated by Sandoz, while the chloroquine phosphate was developed by Bayer Pharmaceuticals.
They also added that the products will be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible,”
President Donald J. Trump has been repeatedly pushing for a quick solution to end the pandemic touting the anti-malaria drugs as a possible coronavirus “game changer,” despite concerned warnings from health officials that not enough is known about the drug’s effects on COVID-19 patients.
Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases and a government’s top infectious disease expert, said during a press briefing earlier this month that much of what is known about the drug is based on “anecdotal reports.”